主页文献库搜索
An alternative schedule of oral vinorelbine tested as 2-line treatment on eld...

de Petris(L),Migliorino(M R),de Santis(S),... J Clin Oncol 0000-00-00

...mos; actuarial median OS (events:61%): 4 mos. Evaluation of clinical benefit is ongoing.,The weekly schedule of O-VNB is...

The impact and perception of mandatory tumor biopsies (Bx) for correlative st...

Agulnik(M),Oza(A M),Pond(G R),Siu(L L) J Clin Oncol 0000-00-00

...MOs responded. Correlative testing of bx specimens was considered worthwhile by 96% of MOs. Clinical trials with mandato...

Cost effectiveness of androgen suppression plus radiation therapy for clinica...

Wang(S J),Herman(T S),Thomas(C R) J Clin Oncol 0000-00-00

...mos of AST, for pts with clinically localized prostate cancer. Quality-of-life utility measures and cost data were obtai...

Gemcitabine and cisplatin (GC) for metastatic breast cancer (BC).

Gerson(R),Fuentes(H),Serrano(A),Villalobos(A) J Clin Oncol 0000-00-00

...mos, range 2 to 15. Mean TTPd 7.9 +/- 4.0 mos, range: 2 - 20. Twelve deaths has been registered (63.1%). Mean survival: ...

Efficacy and influence of neoadjuvant epirubicin/vinorelbine chemotherapy (EN...

Brandi(M),Cataldi(A),Di Corato(G),Altieri(... J Clin Oncol 0000-00-00

886 Background: IBC is the most aggressive form of breast cancer. The introduction of chemotherapy(CT) in multimodality ...

Treatment of unresectable or metastatic gallbladder cancer with single-agent ...

Gallardo(J),Rubio(B),Barajas(O),Villanueva... J Clin Oncol 0000-00-00

...mos. vs 7 mos. for the entire population, 14.1 mos. vs 9 mos. for responders, and 6.1 mos. vs. 5 mos. for non-responders...

Concurrent split course hyperfractionated radiotherapy (Hfx RT), cisplatin (D...

Horwitz(E M),Harris(J),Langer(C J),Nicolao... J Clin Oncol 0000-00-00

...mos, MST is 12.1 mos with est. 1- & 2-yr OS rates of 50.2% (95% CI: 40.0, 59.6) & 25.9% (17.3, 35.3). Median & 1-yr PFS ...

Combination of consecutive low-dose cisplatin with ifosfamide and epirubicin ...

Shimizu(Y),Katase(K),Shimizu(K),Sakurai(S)... J Clin Oncol 0000-00-00

...MOS) after the start of CLD-IEP for all 37 pts was 17.5 months (range, 2.7 to 61.5). MOS was 20.8 months in the responde...

Therapy with alpha interferon for advanced and metastatic giant cell tumor of...

Gonzalez Vela(J L),Cuervo Lozano(C E),Sepu... J Clin Oncol 0000-00-00

...mos.,the remaining pt with humeral and shoulder soft tissue involvement has important radiological and physical improvem...

Gemcitabine and epirubicin in patients with malignant pleural mesothelioma (M...

Okuno(S H),Delaune(R),Sloan(J),Aubry(M-C),... J Clin Oncol 0000-00-00

...mos (range 1.8-7.5). Median time to progression was 4.4 mos (95% CI: 2.7-5.6), and the median survival was 5.7 mos (95% ...

上一页 688 689 690 691 692 693 694 695 696 下一页 692 / 共 704

联系地址

山东省济南市章丘区文博路2号

齐鲁师范学院 genelibs生信实验室

山东省济南市高新区舜华路750号

大学科技园北区F座4单元2楼

电话: 0531-88819269

微信公众号

关注微信订阅号,实时查看信息,关注医学生物学动态。


商务邮箱

E-mail: [email protected]